CCOP - Michigan Cancer Research Consortium

Summary

CCOP - Michigan Cancer Research Consortium is a medical facility located in undefined, undefined. This center is recognized for care of Breast Cancer, Lung Cancer, Prostate Cancer, Ovarian Cancer, Cancer and other specialties. CCOP - Michigan Cancer Research Consortium is involved with conducting 355 clinical trials across 493 conditions. There are 39 research doctors associated with this hospital, such as Tareq Al Baghdadi, Elie G. Dib, Samir Narayan, and Paul Swiecicki.

Top PIs

Clinical Trials running at CCOP - Michigan Cancer Research Consortium

Breast Cancer

Cancer

Skin Cancer

Ovarian Cancer

Pancreatic Cancer

Breast cancer

Bladder Cancer

Liver Cancer

Prostate Cancer

Lung Cancer

Paclitaxel

for Breast Cancer

The primary objective of this pharmacokinetics study is to compare the maximum concentration level of paclitaxel in patients with low/sarcopenic skeletal muscle area (SMA), at the end of a 2-3 hour paclitaxel infusion, to the maximum level in patients with normal SMA at the end of a standard 1-hour infusion with the goal of determining whether lengthening the infusion in patients with low/sarcopenic SMA normalizes the levels to those of patients with normal SMA.

Recruiting

3 awards

Phase 4

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.

Recruiting

2 awards

Phase 3

19 criteria

Chemotherapy + Hormone Therapy

for Breast Cancer

This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.

Recruiting

2 awards

Phase 3

19 criteria